Funder: American Society of Gene & Cell Therapy
Due Dates: December 15, 2026 (Application deadline, 11:59 p.m. Eastern Time)
Funding Amounts: One $50,000 award per year for up to two years
Summary: Supports translational or near-clinical-stage research advancing genetic medicines for Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, or Canavan disease.
Key Information: Funding covers direct research expenses only; salary support and indirect costs are excluded.
Description
The NTSAD-ASGCT Translational Research Fellowship is a joint initiative of the National Tay-Sachs & Allied Diseases Association (NTSAD) and the American Society of Gene & Cell Therapy (ASGCT). The inaugural program supports promising translational or near-clinical-stage research with clear potential to advance innovative genetic medicines toward clinical application.
The fellowship focuses on Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, and Canavan disease. It supports postdoctoral fellows, research scientists, and clinician scientists working to bridge scientific discovery and new therapies for these rare neurogenetic diseases. NTSAD administers the funding, while both organizations coordinate scientific peer review.
